Early observations and pilot data that first suggested a new direction
Severe asthma affects 5-10% of all asthma patients but accounts for over 50% of asthma healthcare costs, with many patients dependent on chronic oral corticosteroids (OCS) despite high-dose inhaled corticosteroids and long-acting bronchodilators. The recognition that severe asthma is not a single disease but a collection of distinct endotypes — characterized by different inflammatory pathways — opened the door to targeted biologic therapy. Omalizumab (anti-IgE), the first biologic approved for asthma, demonstrated in the EXTRA trial and earlier pivotal studies that targeting allergic inflammation could reduce exacerbations by 25-50% in patients with elevated IgE and allergic sensitization. This proof of concept that asthma could be treated by targeting specific immune pathways rather than broadly suppressing inflammation with steroids launched the era of precision respiratory medicine.
Landmark RCTs and pivotal trials that established the evidence base
The anti-IL-5 biologics established eosinophilic inflammation as the dominant treatable trait in severe asthma. The DREAM trial (mepolizumab) demonstrated a 48% reduction in exacerbations in patients with severe eosinophilic asthma, with the MENSA trial confirming a 53% reduction and leading to FDA approval. Benralizumab (anti-IL-5 receptor alpha), which depletes eosinophils via antibody-dependent cell-mediated cytotoxicity, showed similar efficacy in the CALIMA and SIROCCO trials with the advantage of every-8-week dosing. The VENTURE and ZONDA trials demonstrated that anti-IL-5 agents could also reduce OCS dependence, with median OCS dose reductions of 50-75% — addressing one of severe asthma's most debilitating treatment burdens. Blood eosinophil count emerged as a reliable, accessible biomarker for predicting biologic response.
Follow-up studies, subgroup analyses, and real-world validation
Dupilumab (anti-IL-4 receptor alpha, blocking both IL-4 and IL-13) broadened the biologic target population with the LIBERTY ASTHMA QUEST trial showing a 48% reduction in severe exacerbations across a broader range of type 2 inflammation markers (eosinophils, FeNO, IgE). Uniquely, dupilumab also demonstrated significant improvements in FEV1 (0.32L improvement), suggesting an impact on airway remodeling beyond inflammation control. Tezepelumab (anti-TSLP), targeting an epithelial alarmin upstream of multiple type 2 inflammatory cascades, showed in the NAVIGATOR trial a 56% exacerbation reduction in severe asthma regardless of baseline eosinophil count — the first biologic effective across both eosinophilic and non-eosinophilic severe asthma. This upstream approach suggested that even patients without classic type 2 biomarker elevation could benefit from biologic therapy, expanding the treatable population significantly.
Integration into clinical practice guidelines and recommendations
GINA 2024 Step 5 recommends phenotyping patients before biologic initiation, using blood eosinophils, FeNO, total IgE, and allergy testing to guide selection. Anti-IL-5/5R agents (mepolizumab, benralizumab) are preferred for severe eosinophilic asthma (blood eos ≥300/mcL). Dupilumab is positioned for broader type 2 inflammation (eosinophilic and/or high FeNO, particularly with comorbid atopic dermatitis or nasal polyps). Tezepelumab is recommended when type 2 biomarkers are low or for patients who have failed other biologics. The ATS/ERS Severe Asthma guidelines emphasize systematic assessment of adherence, inhaler technique, comorbidities, and triggers before initiating biologics. OCS reduction is now a primary treatment goal, with biologics viewed as OCS-sparing agents.
GINA 2024 Report — Step 5 Severe Asthma Management
Phenotype-guided biologic selection: anti-IgE for allergic, anti-IL-5/5R for eosinophilic, anti-IL-4Rα for broad type 2, anti-TSLP for wider eligibility
ATS/ERS Guidelines on Severe Asthma
Systematic assessment before biologics (adherence, technique, comorbidities); biologic therapy for patients with confirmed severe asthma despite optimized standard therapy
NICE Technology Appraisals for Severe Asthma Biologics
Biologics recommended for severe eosinophilic/allergic asthma meeting specific biomarker thresholds; 12-month treatment trial with reassessment
Now
Current standard of care and ongoing research directions
Severe asthma biologic therapy in 2025-2026 is the flagship example of precision medicine in respiratory care. Six approved biologics target five distinct molecular pathways, with treatment selection guided by a growing biomarker toolkit. The concept of 'clinical remission' in asthma — defined as no exacerbations, no OCS use, symptom control, and stable/improved lung function — is now a realistic treatment goal for many biologic-treated patients. Itepekimab (anti-IL-33) and other novel targets are in development. Head-to-head biologic trials (CAPTAIN, MANDALA vs comparators) are informing treatment algorithms. Remaining challenges include defining optimal treatment duration (can biologics be stopped?), addressing the 20-30% of severe asthma patients who do not respond to any current biologic, and extending access in resource-limited settings where biologics remain prohibitively expensive.
How are blood eosinophils used to guide biologic selection in severe asthma?+
Blood eosinophils ≥300/mcL strongly predict response to anti-IL-5 agents (mepolizumab, benralizumab) and dupilumab. Higher counts (≥500/mcL) predict greater benefit. Eosinophils 150-300/mcL suggest benefit from dupilumab or tezepelumab. Counts <150/mcL with low FeNO suggest non-type 2 asthma where tezepelumab may be the only biologic option.
Can asthma biologics enable oral corticosteroid discontinuation?+
Yes. The VENTURE (dupilumab), ZONDA (benralizumab), and SIRIUS (mepolizumab) trials demonstrated median OCS dose reductions of 50-75%, with 40-50% of patients achieving complete OCS discontinuation. OCS reduction should be gradual to avoid adrenal crisis, with monitoring for adrenal insufficiency during taper.
What differentiates tezepelumab from other asthma biologics?+
Tezepelumab targets TSLP, an epithelial alarmin released upstream of multiple inflammatory cascades. Unlike anti-IL-5 or anti-IL-4Rα agents, it is effective regardless of baseline eosinophil count, potentially benefiting both type 2-high and type 2-low severe asthma. This makes it the broadest-eligibility biologic and potentially the only option for patients without elevated type 2 biomarkers.
Can asthma biologics be discontinued after achieving remission?+
This is an active research question. Limited discontinuation studies suggest that many patients relapse within 3-12 months of stopping biologics, though a subset maintains remission. Biomarkers predicting successful discontinuation are under investigation. Current practice generally continues biologic therapy indefinitely, with periodic reassessment of disease activity and need.
